Cram

Jump to

Margins to pick up in H2, will meet FY15 guidance: Dishman

Dishman Pharma‘s margins were down due to stock building but they are expected to pick up in the second half of this fiscal, says company MD Arpit Vyas.
Dishman pins hopes on China unit

JR Vyas, MD, Dishman Pharma says Carbogen Amcis anticipates a turnover of 96 million this fiscal and a turnover of 106 million the next fiscal year.
Ind Swift restructures, growth seen at 30%: Management

Dr.Gopal Munjal, chairman of pharma player, Ind Swift, joins CNBC-TV18 to give an outlook to his business and the industry. Ind Swift is restructuring and the management is confident of maintaining growth at 30% at year-end.
Piramal sees revival in CRAMs, growth in OTC biz

Ajay Piramal, chairman of the company talks to CNBC-TV18's Ekta Batra about the outlook for the company.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Cram

Margins to pick up in H2, will meet FY15 guidance: Dishman

Dishman pins hopes on China unit

Ind Swift restructures, growth seen at 30%: Management

Piramal sees revival in CRAMs, growth in OTC biz